Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of BPC-157 and GHK-Cu — mechanism, side effects, legal status, and pricing.
BPC-157 is a synthetic pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a 15-amino-acid fragment of body protection compound (BPC), a protein isolated from human gastric juice. It is research-only, not approved by the FDA or any major regulator for human use, and almost all published evidence comes from rodent models.
GHK-Cu is the copper(II) complex of the human tripeptide glycyl-L-histidyl-L-lysine, first identified in human plasma by Loren Pickart in 1973. Plasma GHK declines with age. It is best established as a topical cosmetic ingredient for photoaged skin; it is NOT an FDA-approved drug in any jurisdiction.
BPC-157
GHK-Cu
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
BPC-157
GHK-Cu
COA corpus from Disclosed Labs — independently tested batches only.
BPC-157
338
COAs
99.3%
Avg purity
16
Labs
GHK-Cu
225
COAs
99.6%
Avg purity
17
Labs
BPC-157 and GHK-Cu are both among peptides under FDA review for the Category 1 (503A) list; if added, they would require a prescription to be compounded by registered 503A/503B pharmacies — they are not yet authorized. In April 2026 the FDA removed 12 peptides from Category 2, which does not place them on the Category 1 list or authorize compounding. The FDA's Pharmacy Compounding Advisory Committee is advisory and meets July 23–24, 2026 to review nominations and make recommendations to the FDA.
Extensive rodent data from the Sikiric group and others report accelerated healing of tendon, ligament, muscle, and gastrointestinal injury, plus cytoprotective effects in models of NSAID and alcohol damage (PMID 21548867, 30915550). Preclinical tendon studies demonstrate enhanced growth hormone receptor expression in fibroblasts (PMID 25415472) and promote tendon outgrowth, cell survival, and cell migration (PMID 21030672). Published human clinical evidence is limited; an early oral formulation (PL 14736) was explored for inflammatory bowel disease but has not progressed to approval. No peer-reviewed trial validates the injectable doses (200–500 mcg) commonly used on the grey market, and pharmacokinetics and long-term safety in humans are not well characterized.
Key references
GHK was identified in human plasma by Pickart in 1973 and characterized as a copper-binding tripeptide in Nature in 1980 (PMID 7453802). Controlled topical studies in photoaged human skin have shown improvements in skin appearance and density with ~2% formulations. Pickart's 2014 review 'GHK and DNA: resetting the human genome to health' (PMID 25302294) and 2018 Int J Mol Sci review 'Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data' (PMID 29986520) summarize transcriptomic data showing modulation of thousands of genes involved in tissue repair, DNA repair, antioxidant defense, and anti-inflammation. The SubQ protocols circulating in the peptide community (typically 1-2 mg) are not supported by controlled human trials.
Key references
BPC-157 (Recovery) and GHK-Cu (Cosmetic) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
Cheapest verified BPC-157: live prices, vendors & COA data
The cheapest verified BPC-157 by price-per-mg — a live board of in-stock vendors with COAs on file. Lab data from 16 labs across 338 COAs.
Cheapest verified GHK-Cu: live prices, vendors & COA data
The cheapest verified GHK-Cu by price-per-mg — a live board of in-stock vendors with COAs on file. Lab data from 17 labs across 219 COAs.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs